Načítá se...
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US Patients
BACKGROUND: Multiple sclerosis (MS) registry data, primarily from Europe, suggest that treatment with natalizumab delays time to relapse compared with platform therapy (interferon beta/glatiramer acetate). OBJECTIVE: This study uses US administrative claims data and propensity score matching (PSM) t...
Uloženo v:
| Vydáno v: | CNS Drugs |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Springer International Publishing
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4513191/ https://ncbi.nlm.nih.gov/pubmed/26113055 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40263-015-0251-1 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|